Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era

Abstract

In the recent cART era, despite frequent high-risk features, the 2-year overall survival of HIV-DLBCL patients reaches 75%. Outcomes after R-CHOP therapy are similar to those of HIV-negative patients with similar aaIPI.